Greenwich LifeSciences, Inc.
Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company developing cancer immunotherapies, focused on GLSI-100, a combination of the HER2/neu peptide GP2 and the immune adjuvant GM-CSF. Its lead candidate is being evaluated to prevent breast cancer recurrence in HER2-positive patients at… From the company’s description.
Over the twelve months to Jun 30, 2026, Greenwich LifeSciences, Inc. reported a net loss of $21.68M. Operations used $12.49M in cash. In fiscal 2025, it reported a net loss of $19.36M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Greenwich LifeSciences, Inc. does
In the company’s own words
Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company developing cancer immunotherapies, focused on GLSI-100, a combination of the HER2/neu peptide GP2 and the immune adjuvant GM-CSF. Its lead candidate is being evaluated to prevent breast cancer recurrence in HER2-positive patients at high risk after surgery and trastuzumab-based treatment. The Phase III Flamingo-01 trial is enrolling in the United States and Europe. GP2 is administered by intradermal injection and is designed to stimulate an immune response against HER2/neu-expressing cancer cells. The company’s earlier clinical program includes Phase I studies and a completed Phase IIb breast cancer trial; it also identifies other HER2/neu-expressing cancers as potential future indications. Greenwich licenses worldwide GP2-related technology from the Henry M. Jackson Foundation and relies on third-party manufacturers for clinical materials. It has no reportable business segments described in the business overview. The company does not yet market products and has no sales, marketing, or distribution capability. Its website is www.greenwichlifesciences.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- STAFFORD, TX
- Fiscal year end
- December
- CIK
- 1799788
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Greenwich LifeSciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Greenwich LifeSciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Greenwich LifeSciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Greenwich LifeSciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Greenwich LifeSciences, Inc.'s last four quarterly filings that the numbers alone won't show?”